Top

Published in:

01-09-2013 | Endocrine Tumors

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)

Authors: Giovenzio Genestreti, MD, Luca Ampollini, MD, Marco Angelo Burgio, MD, Luigi Rolli, MD, Stefano Sanna, MD, Emanuela Scarpi, MSc, Manuela Monti, BSc, Luca Burgio Salvatore, MD, Luciana Giannone, BSc, Antonio Santo, MD, Maurizio Mezzetti, MD, Claudia Casanova, MD, Roberta Buosi, MD, Michele Rusca, MD, Dino Amadori, MD, Giampaolo Gavelli, MD

Published in: Annals of Surgical Oncology | Issue 9/2013

Abstract

Background

This multicenter analysis evaluated patient outcome and clinical pathologic features of thymic epithelial tumors after complete surgical resection and adjuvant treatment.

Methods

Histologic classification and clinical staging were performed according to WHO classification and Masaoka staging system, respectively.

Results

We analyzed 62 patients, 20 (32 %) of whom had myasthenia at diagnosis. Clinical and pathologic staging was as follows: 31 (50 %) and 30 (48 %) patients had stage I disease, 19 (30 %) and 22 (35 %) stage II, 5 (8 %) and 3 (6 %) stage III, 2 (4 %) and 2 (3 %) stage IVa, and 5 (8 %) and 5 (8 %) stage IVb, respectively. Histologic examination revealed 11 (19%) type A tumors, 19 (30%) type AB tumors, 7 (12 %) type B1 tumors, 11 (17 %) type B2 tumors, 11 (17 %) type B3 tumors, and 3 (5 %) type C tumors. Adjuvant therapies comprised chemotherapy in 3 (5 %) patients and radiotherapy in 16 (26 %) patients. Median follow-up was 71 months (range 1–145). DFS and OS at 48, 60, and 72 months were 89 and 89 %, 86 and 97 %, and 95% and 92%, respectively. Myasthenia at the onset of disease (P = 0.18 for DFS; P = 0.97) and tumor size >5 cm (P = 0.94 for DFS; P = 0.56) were not prognostic factors.

Conclusions

TETs are rare and indolent tumors. Complete surgical resection followed by adjuvant therapies, such as chemotherapy and/or radiotherapy, in patients at risk of recurrence show very good DFS and OS results, even in cases with radically resected pleural-pulmonary metastases.

Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol. 1978;9:495–515.PubMedCrossRef

Lattes R. Thymomas and other tumors of the thymus: an analysis of 107 cases. Cancer. 1962;15:1224–60.CrossRef

Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Talyor WF. Thymoma: a clinicopathologic review. Cancer. 1987;60:2727–43.PubMedCrossRef

Loehrer PJ Sr, Wick MR. Thymic malignancies. Cancer Treat Res. 2001;105:277–302.PubMedCrossRef

LeGolvan DP, Abell MR. Thymomas. Cancer. 1977;39:2142–57.PubMedCrossRef

Masaoka A, Hashimoto T, Shibata K, Yamakowa Y, Nakamae K. Thymomas associated with pure red cell aplasia: histology and following studies. Cancer. 1989;64:1872.PubMedCrossRef

Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485–92.PubMedCrossRef

Batata MA, Martini N, Huvos AG, Aguilar RI, Beattie EJ Jr. Thymomas: clinico-pathologic features, therapy and prognosis. Cancer. 1974;34:389–96.PubMedCrossRef

Monden Y, Nakahara K, Iioka S, et al. Recurrence of thymoma: clinico-pathological features, therapy, and prognosis. Ann Thorac Surg. 1985;39:165–9.PubMedCrossRef

10.

Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymoma: results of 241 operated cases. Ann Thorac Surg. 1991;51:152–6.PubMedCrossRef

11.

Bernatz PE, Khonsari S, Harrison EG Jr, Taylor WF. Thymoma: factors influencing prognosis. Surg Clin North Am. 1973;53:885–92.PubMed

12.

Quintanilla-Martinez L, Wilkins EW Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer. 1994;74:606–17.PubMedCrossRef

13.

Sugiura H, Morikawa T, Ito K, Ono K, Okushiba S, Satoshi K, Katoh H. Long-term results of surgical treatment for invasive thymoma. Anticancer Res. 1999;19(2B):1433–7.

14.

Curran WJ, Kornstein MJ, Brooks JJ, Turrisi AT III. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6:1722–7.PubMed

15.

Haniuda M, Miyazawa M, Yoshida K, et al. Is postoperative radiotherapy for thymoma effective? Ann Surg. 1996;224:219–24.PubMedCrossRef

16.

Uematsu M, Yoshida H, Kondo M, et al. Entire hemithorax irradiation following complete resection in patients with Stage II–III invasive thymoma. Int J Radiat Oncol Biol Phys. 1996;35:357–60.PubMedCrossRef

17.

Latz D, Schraube P, Oppitz U, et al. Invasive thymoma: treatment with postoperative radiation therapy. Radiology. 1997;204:859–64.PubMed

18.

Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1.320 patients from Japan. Ann Thorac Surg. 2003;76:878–85.PubMedCrossRef

19.

Rosai J. Histological typing of tumours of the thymus. In: WHO International histological classification of tumours, 2nd ed. New York: Springer-Verlag; 1999:5–15.

20.

Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer. 1991;68(1):30–3.PubMedCrossRef

21.

Loehrer PJ Sr, Perez CA, Roth LM, Greco A, Livingston RB, Einhorn LH. Chemotherapy for advanced thymoma. Preliminary results of an intergroup study. Ann Intern Med. 1990;113:520–4.PubMedCrossRef

22.

Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef

23.

Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187–220.

24.

Okereke IC, Kesler KA, Morad MH, et al. Prognostic indicators after surgery for thymoma. Ann Thorac Surg. 2010;89:1071–7.PubMedCrossRef

25.

Monden Y, Nakahara K, Nanjo S, Fujii Y, Matsumura A, Masaoka A, Kawashima Y. Invasive thymoma with myasthenia gravis. Cancer. 1984;54:2513–8.PubMedCrossRef

26.

Maggi G, Casadio C, Cavallo A, Cianci R, Molinatti M, Ruffini E. Thymectomy in myasthenia gravis. Results of 662 cases operated upon in 15 years. Eur J Cardio-Thorac Surg. 1989;3:504–11.

27.

Wright CD, Wain JC, Wong DR, Donahue DM, Gaissert HA, Grillo HC, Mathisen DJ. Predictors of recurrence in thymic tumors: importance of invasion, and size. World Health Organization histology. J Thorac Cardiovasc Surg. 2005;130:1413–21.PubMedCrossRef

28.

Rieker RJ, Hoegel J, Morresi-Hauf A, Hofmann WJ, Blaeker H, Penzel R, Otto HF. Histologic classification of thymic epithelial tumors: comparison of established classification schemes. Int J Cancer. 2002;98:900–6.PubMedCrossRef

29.

Gupta R, Marchevsky AM, McKenna RJ, Wick M, Moran C, Zakowski MF, Suster S. Evidence based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med. 2008;132:926–30.PubMed

30.

Okereke IC, Kesler KA, Morad MH. Prognostic indicators after surgery for thymoma. Ann Thorac Surg. 2010;89:1071–9.PubMedCrossRef

31.

Lucchi M, Melfi F, Dini P, et al. Neoadjuvant chemotherapy for stage III and IV-A thymoma; a single institution experience with long term follow-up. J Thorac Oncol . 2006;1:308–13.PubMedCrossRef

32.

Okereke IC, Kesler KA, Freeman RK, et al. Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg. 2012;93:1668–72.PubMedCrossRef

33.

Bott MJ, Wang H, Travis W, et al. Management and outcomes of relapse after treatment for thymoma and thymic carcinoma. Ann Thorac Surg. 2011;92:1984–92.PubMedCrossRef

34.

Welsh JS, Wilkins KB, Green R, Bulkley G, Askin F, Diener-West M, Howard SP. Association between thymoma and second neoplasms. JAMA. 2000;283:1142–3.PubMedCrossRef

Title: Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)
Authors: Giovenzio Genestreti, MD
Luca Ampollini, MD
Marco Angelo Burgio, MD
Luigi Rolli, MD
Stefano Sanna, MD
Emanuela Scarpi, MSc
Manuela Monti, BSc
Luca Burgio Salvatore, MD
Luciana Giannone, BSc
Antonio Santo, MD
Maurizio Mezzetti, MD
Claudia Casanova, MD
Roberta Buosi, MD
Michele Rusca, MD
Dino Amadori, MD
Giampaolo Gavelli, MD
Publication date: 01-09-2013
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 9/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3018-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

Gd-EOB-DTPA-Enhanced MRI is Better than MDCT in Decision Making of Curative Treatment for Hepatocellular Carcinoma

Outcomes and Prognostic Factors of Post-irradiation and de novo Sarcomas of the Head and Neck: A Histologically Matched Case-Control Study

Population-Level Analysis of Pancreatic Neuroendocrine Tumors 2 cm or Less in Size

Embedded Cervical Esophagogastrostomy: A Simple and Convenient Method Using a Circular Stapler After Esophagectomy for Esophageal Carcinomas

Diagnostic Ureteroscopy Independently Correlates with Intravesical Recurrence after Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Esophagojejunal Reconstruction After Total Gastrectomy for Gastric Cancer Using a Transorally Inserted Anvil Delivery System